uniQure

YTD

ALL

Trade uniQure 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About QURE

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems.

CEO

Matthew C. Kapusta

CEOMatthew C. Kapusta

Employees

209

Employees209

Headquarters

Amsterdam, Noord-Holland

HeadquartersAmsterdam, Noord-Holland

Founded

2012

Founded2012

Employees

209

Employees209

QURE Key Statistics

Market cap

582.16M

Market cap582.16M

Price-Earnings ratio

-2.60

Price-Earnings ratio-2.60

Dividend yield

—

Dividend yield—

Average volume

6.26M

Average volume6.26M

High today

$9.78

High today$9.78

Low today

$8.88

Low today$8.88

Open price

$9.04

Open price$9.04

Volume

1.09M

Volume1.09M

52 Week high

$71.50

52 Week high$71.50

52 Week low

$7.76

52 Week low$7.76

Stock Snapshot

With a market cap of 582.16M, uniQure(QURE) trades at $9.45. The stock has a price-to-earnings ratio of -2.60.

On 2026-03-05, uniQure(QURE) stock moved within a range of $8.88 to $9.78. With shares now at $9.45, the stock is trading +6.4% above its intraday low and -3.4% below the session's peak.

Trading volume for uniQure(QURE) stock has reached 1.09M, versus its average volume of 6.26M.

Over the past 52 weeks, uniQure(QURE) stock has traded between a high of $71.50 and a low of $7.76.

QURE News

TipRanks 15m

Concerns spurred by FDA push for ‘sham’ brain surgery trial, Bloomberg says

UniQure’s (QURE) gene therapy for Huntington’s disease has shown promising early results, but the FDA is requiring a new trial with a sham-surgery placebo group...

TipRanks 3d

uniQure reports FY25 EPS ($3.46) vs ($4.92) last year

Reports FY25 revenue $16M vs $27.119M last year. “In 2025, we presented compelling 36-month clinical data from AMT-130 that we believe meaningfully demonstrate...

TipRanks 6d

UniQure N.V. Lawsuit Follows Sharp Stock Drop After FDA Feedback on AMT-130

Investors are focused on allegations that optimistic statements about a key Huntington’s disease program masked regulatory uncertainty until new FDA feedback em...

Analyst ratings

57%

of 14 ratings

Buy

42.9%

Hold

57.1%

Sell

People also own

Based on the portfolios of people who own QURE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.